Actinium Pharmaceuticals, Inc. (ATNM): CFO Matt David appointed

Events in this filing

Item 5.02 as filed

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
Appointment of Chief Financial Officer
On October 14, 2026, Matt David, M.D., age
49, commenced service as Chief Financial Officer and principal financial officer of Actinium Pharmaceuticals, Inc. (the
“Company”). The Company entered into an offer letter with Dr. David on September 30, 2026 (the “Offer
Letter”). Dr. David brings more than 20 years of life sciences, corporate finance, capital markets and investor relations
experience. He served as Chief Financial Officer of CorMedix Inc. from May 2020 to September 2025 and subsequently as its Chief
Business Officer through October 2026. He was Interim Chief Executive Officer from October 2021 to May 2022. At CorMedix, he
oversaw finance, capital markets, investor relations and IT, and supported the acquisition of Melinta Therapeutics in 2025 to diversify the company’s commercial portfolio. Previously, he
held leadership and advisory roles at Ovid Therapeutics and in healthcare investment banking including positions at BofA Merrill
Lynch, Piper Jaffray and Thomas Weisel Partners. He holds an M.D. from New York University School of Medicine and a B.A. from
Dartmouth College.
There are no arrangements or understandings between
Dr. David and any other person pursuant to which he was selected as an officer of the Company. There are no family relationships between
Dr. David and any director or executive officer of the Company, and Dr. David has no direct or indirect material interest in any transaction
required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Under the Offer Letter, Dr. David will receive
an annual base salary of $450,000, a target annual performance bonus of 40% of base salary and a $150,000 sign-on bonus. He will also
receive a guaranteed prorated target bonus for 2026, subject to continued employment through the applicable payment date. In connection
with his appointment, Dr. David was granted an option to purchase 250,000 shares of the Company’s common stock and 325,000 restricted
stock units under the Company’s 2026 Employment Inducement Award Plan. The option has an exercise price equal to the closing market
price on the grant date and vests over four years. The RSUs include time-based vesting and performance-based vesting tied to corporate
milestones. The awards are subject to time-based and performance-based vesting conditions and were granted in accordance with Section
711(a) of the NYSE American Company Guide. The Offer Letter also provides for customary severance benefits upon certain qualifying terminations of employment, including salary continuation,
continued health benefits, bonus payments and equity vesting acceleration. Enhanced severance benefits apply in connection with certain
terminations following a change in control, subject to the terms and conditions of the Offer Letter. The Inducement Plan was adopted by
the Board on September 2, 2026, without stockholder approval, pursuant to Section 711(a) of the NYSE American Company Guide. The full
text of the Inducement Plan is incorporated by reference as Exhibit 10.1 to this Current Report on Form 8-K.